Prosecution Insights
Last updated: April 19, 2026

Examiner: HILL, MYRON G

Tech Center 1600 • Art Units: 1632 1648 1671

This examiner grants 66% of resolved cases

Performance Statistics

66.4%
Allow Rate
+6.4% vs TC avg
719
Total Applications
+19.8%
Interview Lift
1144
Avg Prosecution Days
Based on 685 resolved cases, 2023–2026

Rejection Statute Breakdown

5.9%
§101 Eligibility
17.0%
§102 Novelty
28.2%
§103 Obviousness
31.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18452524 CONFORMATIONAL EPITOPES IN RESPIRATORY SYNCYTIAL VIRUS G PROTEIN CENTRAL CONSERVED REGION Non-Final OA The Regents of the University of California
18289622 NON-VIRAL DNA VECTORS FOR VACCINE DELIVERY Non-Final OA Generation Bio Co.
18411568 Ferritin Proteins Non-Final OA SANOFI
17629309 IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USING Non-Final OA University of Louisville Research Foundation, Inc.
17776211 ANTI-RS VIRUS N PROTEIN-RECOGNIZING ANTIBODY, AND IMMUNOASSAY METHOD AND IMMUNOASSAY APPARATUS USING THE ANTIBODY Final Rejection Denka Company Limited
18314980 RESPIRATORY SYNCYTIAL VIRUS VACCINE Final Rejection ModernaTX, Inc.
17796401 RESPIRATORY VIRUS IMMUNIZING COMPOSITIONS Final Rejection ModernaTX, Inc.
18558875 SARS-COV-2 SUBUNIT VACCINE Non-Final OA LABORATORIOS HIPRA, S.A.
18554935 MODIFIED VIRUS-LIKE PARTICLES OF BACTERIOPHAGE AP205 Non-Final OA SAIBA AG
18285576 SARS-COV-2 POLYPEPTIDES AND USES THEREOF Non-Final OA IAMA FRANCE
18549625 LATERAL FLOW TEST METHODS Non-Final OA Stichting Wageningen Research
17477077 ZIKA VIRUS VACCINES USING VIRUS-LIKE PARTICLES Non-Final OA Wisconsin Alumni Research Foundation (WARF)
18549058 DETECTION OF INFECTIOUS AGENT BASED ON RECOMBINASE POLYMERASE AMPLIFICATION COMBINED WITH A MAGNETIC FIELD-ENHANCED AGGLUTINATION Non-Final OA HORIBA ABX SAS
18458789 DOWNSTREAM PROCESS FOR PURIFICATION OF VIRAL PROTEINS WITH HYDROPHOBIC MEMBRANE DOMAIN FOR USE IN VACCINE COMPOSITIONS Non-Final OA Novavax, Inc.
18548080 VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 Non-Final OA EYEGENE INC.
18008393 LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS Non-Final OA The United States of America, as represented by the Secretary, Department of Health and Human
18271250 METHODS AND COMPOSITIONS FOR MODULATING THE INTERACTION BETWEEN ADENO-ASSOCIATED VIRUS (AAV) AND THE AAV RECEPTOR (AAVR) FOR ALTERED BIO-DISTRIBUTION OF AAV Non-Final OA THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
18029806 METHODS OF DETECTING ANTI-AAV ANTIBODIES Non-Final OA Sangamo Therapeutics, Inc.
18258501 MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY Non-Final OA EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET
17924193 COMPOSITION OF NANOPARTICLES AS CARRIER FOR HPV-DERIVED IMMUNOGENIC FRAGMENTS Non-Final OA UNIVERSITAT HEIDELBERG
17843445 MULTIVALENT INFLUENZA VACCINES Final Rejection SANOFI PASTEUR INC.
17472721 Self-assembled protein nanoparticle and its applications thereof Final Rejection Ming-Chung Kan

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month